The COVID-19 pandemic has underscored key weaknesses in the biopharma
industry’s complex global supply chain, and now a top adviser for the
Trump administration is calling on Congress to push for more
manufacturing in Puerto Rico.
In an interview with the Washington Examiner, White House trade
adviser Peter Navarro faulted a “broken system” that pushes
manufacturing offshore. He called on Congress to use the next round of
COVID-19 relief to incentivize manufacturing on the island territory.
Previously, a tax provision allowed U.S. companies to avoid paying
federal taxes on profits from operations in Puerto Rico, but Congress
phased that out over time, the Examiner reports. Plus, utility costs are
significantly higher there than in the U.S., which has also led to a
reduction in manufacturing. Pharma companies themselves have shuttered a
number of drug plants in Puerto Rico in recent years.
“If this crisis has taught us anything across party lines, it is that
we do indeed need to bring home the pharmaceutical supply chain, that
it is not just a public health issue, but a national security issue and
an economic security issue,” Navarro told the publication.
The Trump administration has already made moves to bolster U.S. drug
production in its response to the pandemic. The administration picked a
little-known startup, Phlow Corporation, for a $354 million contract to
produce generic meds and active pharmaceutical ingredients for COVID-19
therapies. And Monday, the government inked a $628 million deal with
Maryland biotech Emergent BioSolutions for potential COVID-19 vaccine
manufacturing.
Aside from the administration’s efforts, lawmakers are working on
their own measures to bring drug production back to the U.S., Stat reports. That’s caused pharma companies to mobilize lobbyists to push back.
https://www.fiercepharma.com/pharma/fiercepharmapolitics-trump-trade-advisor-citing-broken-system-calls-for-more-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.